EUVIMEDEUVIMED entdecken
Crossref

Impact of immunosuppressive therapy on renal and patient survival in rapidly progressive secondary IgA nephropathy

Amir Shabaka iD, Ángel M Sevillano, Javier Vian, Sara Aldana, Antolina Rodríguez-Moreno, Ana Huerta iD, Fernando Hadad, Maria José Reguera-Carmona, Loreto Fernández-Lorente, Joaquín Bande, Isabel Galán-Carrillo, Milagros Sierra-Carpio und 4 weitere

Nephrology Dialysis Transplantation · 06.07.2026

DOI: 10.1093/ndt/gfag158 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 06.07.2026. Verfasst von Amir Shabaka und 15 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario La Paz, Madrid, Spain. Die Arbeit nennt 21 Literaturangaben. Gefördert von: Instituto de Salud Carlos III, European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Secondary IgA nephropathy (IgAN) associated with systemic diseases represents a heterogeneous population in whom renal prognosis and treatment response are poorly defined. Patients with secondary IgAN have been excluded from major trials, and the benefit of adding immunosuppressive therapy to supportive care remains uncertain.

Methods

We conducted a retrospective multicenter cohort study including adults with biopsy-proven rapidly progressive secondary IgAN. Patients received supportive care alone, supportive care plus corticosteroids, or corticosteroids with additional immunosuppression. To address confounding by indication, inverse probability of treatment weighting based on propensity scores was applied, defining treatment escalation as immunosuppressive therapy beyond corticosteroids. Exposure was defined using landmark analyses (primary 30-day; sensitivity 14-day) to reduce immortal time bias. The primary outcome was kidney failure, accounting for death as a competing event. All-cause mortality was assessed using weighted Cox models.

Results

Ninety-two patients were included (mean age 61 ± 16 years; 83% male). Mean estimated glomerular filtration rate at presentation was 17 ± 10 ml/min/1.73 m², and 32% required dialysis. Liver disease was the most frequent underlying condition (51%). Over a median follow-up of 36 months, 32 patients (35%) developed kidney failure and 34 (37%) died. After weighting, baseline covariates were balanced. Treatment escalation was not associated with progression to kidney failure [30-day landmark: subdistribution hazard ratio (SHR) 1.09, 95% confidence interval (CI) 0.35–3.38; 14-day landmark: SHR 1.40, 95% CI 0.49–4.03] or all-cause mortality [30-day: hazard ratio (HR) 1.20, 95% CI 0.34–4.17; 14-day: HR 1.14, 95% CI 0.32–4.08]. Renal survival differed by etiology (log-rank P = .006), with the poorest outcomes in liver disease–associated IgAN. Liver disease (HR 3.16, 95% CI 1.07–9.33) and dialysis at presentation (HR 4.20, 95% CI 1.44–12.28) independently predicted kidney failure.

Conclusion

Rapidly progressive secondary IgAN carries high renal and patient mortality. After accounting for baseline severity, competing risk, and immortal time bias, treatment escalation was not associated with improved renal or patient survival.

Schlagwörter

Stichwörter der Autor:innen

corticosteroidsimmunosuppressionkidney failurerapidly progressive glomerulonephritissecondary IgA nephropathy

Autor:innen und Institutionen

  • Hospital Universitario La Paz, Madrid, Spain.
  • Hospital Universitario Fundación Alcorcón, Madrid, Spain.
  • Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Hospital Marqués de Valdecilla, Santander, Spain.
  • Hospital Clínico San Carlos, Madrid, Spain.
  • Hospital Universitario Puerta de Hierro, Madrid, Spain.

ORCID-Profile: Amir Shabaka, Ana Huerta

Förderung

  • Instituto de Salud Carlos III
  • European Union

Zitieren

APA

Shabaka, A., Sevillano, Á. M., Vian, J., Aldana, S., Rodríguez-Moreno, A., Huerta, A., Hadad, F., Reguera-Carmona, M. J., Fernández-Lorente, L., Bande, J., Galán-Carrillo, I., Sierra-Carpio, M., López-Melero, E., Valdés-Francí, E., Fernández-Juárez, G., & Spanish Group for the Study of Glomerular Diseases (GLOSEN) (2026). Impact of immunosuppressive therapy on renal and patient survival in rapidly progressive secondary IgA nephropathy. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag158

Vancouver

Shabaka A, Sevillano ÁM, Vian J, Aldana S, Rodríguez-Moreno A, Huerta A, et al. Impact of immunosuppressive therapy on renal and patient survival in rapidly progressive secondary IgA nephropathy. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag158

BibTeX
@article{Shabaka2026,
  author = {Shabaka, Amir and Sevillano, Ángel M and Vian, Javier and Aldana, Sara and Rodríguez-Moreno, Antolina and Huerta, Ana and Hadad, Fernando and Reguera-Carmona, Maria José and Fernández-Lorente, Loreto and Bande, Joaquín and Galán-Carrillo, Isabel and Sierra-Carpio, Milagros and López-Melero, Eva and Valdés-Francí, Elena and Fernández-Juárez, Gema and Spanish Group for the Study of Glomerular Diseases (GLOSEN), Spanish Group for the Study of Glomerular Diseases (GLOSEN)},
  title = {Impact of immunosuppressive therapy on renal and patient survival in rapidly progressive secondary IgA nephropathy},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  doi = {10.1093/ndt/gfag158}
}
Kostenlos starten →